Firefly Reports 373% Increase In Pediatric ADHD Scan Volume As Platform Adotoption Grows

Firefly Neuroscience (AIFF) reported a 373% year-over-year increase in pediatric ADHD scans using its Evoke platform. The company attributes this growth to broader adoption across neuropsychiatric practices. Firefly also highlighted a partnership with NeuroSigma to offer the Monarch eTNS System, an FDA-cleared treatment for pediatric ADHD. AIFF's stock traded between $0.62 and $3.15 over the past year, closing Monday at $0.88.

Original reporting
Published Nov 17, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AIFF
Bullish
medium confidence
Mentioned
$AIFF
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AIFFBullishLow
01

Why it matters

The reported 373% YoY pediatric ADHD scan-volume increase is a utilization datapoint that can strengthen the adoption story for Evoke and support longer-term commercialization of a diagnostic-to-treatment model, but it lacks direct financial impact measures.

02

Market read

Traders may view the scan-volume acceleration as incremental evidence of platform adoption, but without revenue or guidance updates it is unlikely to drive a major repricing on its own.

03

What to watch

The piece does not disclose margins, conversion from scans to paid subscriptions, or whether the NeuroSigma Monarch eTNS rollout is already driving incremental demand.

Relevance 5/10Novelty 5/10Timing: today’s news flow, pre-market mention of AIFF around $0.89

Background

Firefly Neuroscience’s Evoke neurodiagnostic platform is FDA 510(k)-cleared, and the company is building an AI-driven neuroscience pipeline using a growing standardized EEG/ERP scan database.

Company-level read

Ticker impact

$AIFFBullishMedium confidence
Context

Firefly reports a 373% YoY increase in pediatric ADHD scan volume on its Evoke platform, citing 4.7-fold growth and expanding adoption.

Expected impact

Likely modest upside bias as traders price in stronger adoption momentum and potential monetization via the NeuroSigma partnership.

Evidence & confidence

The article provides specific utilization growth metrics and links them to database expansion and a diagnostic-to-treatment model, but it does not quantify revenue impact or provide new financial guidance.

Market effects

Supports the narrative that neurodiagnostic platforms are gaining clinical traction in pediatric neuropsychiatry, potentially benefiting sentiment toward AI-enabled EEG/ERP tools.

No clear regional macro linkage beyond US-listed microcap risk appetite.

Limited, as the disclosure is company-specific and tied to FDA-cleared products and a US user network.

Counterpoint

Scan-volume growth may not translate into near-term revenue if reimbursement, pricing per scan, or retention of new sites lags the adoption curve.

Key entities

  • Firefly Neuroscience, Inc.

    Reports 373% YoY pediatric ADHD scan-volume growth on its Evoke platform and highlights partnership-driven treatment commercialization.

  • NeuroSigma

    Partnership announced in September 2026 to offer the Monarch eTNS System through Evoke users.

  • Evoke neurodiagnostic platform

    FDA 510(k)-cleared platform used for objective brain function assessment, including ADHD evaluations.

  • Monarch eTNS System

    FDA-cleared, non-drug prescription treatment for pediatric ADHD to be offered via Evoke user network.

Related articles

$AIFFHighAI 8/10

AI Stock Firefly Neuroscience (NASDAQ: AIFF) Soars on First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) stock surged 32.77% after announcing a partnership with NeuroSigma to expand access to the FDA-cleared Monarch eTNS(R) System, a non-drug treatment for pediatric ADHD. The stock traded at $1.58 on high volume. Firefly's Evoke(TM) platform provides AI-powered brain function analytics to clinicians. According to a 2024 study, approximately 7.1 million U.S. children have been diagnosed with ADHD, with nearly one-third receiving no treatment.

$AIFFHigh

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

$INTCMed

Intel signs first outside customer for 18A process as yields reach 70%

Intel announced its first external customer for the 18A manufacturing process, with yields reaching 70%. CEO Lip-Bu Tan highlighted the improvement from previous 'horrible' levels. The 18A node combines RibbonFET and PowerVia technologies. Intel also partnered with Microsoft for Azure infrastructure using EMIB packaging. The company aims to release internal 14A products by late 2027, with external customers expected in 2028-2029.

$NVDAMed

Nvidia's $332 Billion AI Cloud Bet Has a Second Act

Nvidia (NVDA) announced up to $32B in commitments for neocloud agreements, aiding cloud providers in expanding AI computing power. Revenue will come from hardware sales and potential revenue sharing. Key milestones include securing funding and operational capacity, with $6B in fiscal 2028, $7B in 2029, and $8B from 2032 onwards.